Clik here to view.
EASL 2016: Grazoprevir/ Elbasvir Superior to Sofosbuvir Plus Pegylated...
New research has demonstrated the clear superiority of an oral combination of direct-acting antivirals (DAAs) over a regimen that combines a DAA with pegylated interferon and ribavirin for the...
View ArticleClik here to view.
DDW 2016: Modern DAA Regimens Cost Less Per Cure than Older Hepatitis C...
The cost of treating chronic hepatitis C with sofosbuvir/ledipasvir (Harvoni) with or without ribavirin is lower than the cost of prior interferon-based therapy with first-generation direct-acting...
View ArticleClik here to view.
Successful Hepatitis C Treatment Reduces Portal Hypertension
Direct-acting antiviral therapy that produces a sustained virological response can lead to reduction in portal vein pressure, which causes some of the most serious complications of cirrhosis,...
View ArticleClik here to view.
FDA Approves Gilead's Epclusa Combo Pill for All Hepatitis C Genotypes
On June 28 the U.S. Food and Drug Administration (FDA) approved Gilead Sciences Epclusa, a new once-daily combination pill containing sofosbuvir and velpatasvir, for the treatment of adults with...
View ArticleClik here to view.
AASLD/IDSA Hepatitis C Guidelines Updated to Include New Therapies
The American Association for the Study of Liver Diseases, Infectious Diseases Society of America, and International Antiviral Society-USA this week updated their hepatitis C guidelines to add newly...
View ArticleClik here to view.
Coverage of 21st International AIDS Conference (AIDS 2016)
HIVandHepatitis.com coverage of the 21st International AIDS Conference (AIDS 2016), held July 18-22, in Durban, South Africa. Conference highlights include PrEP and other biomedical HIV prevention,...
View ArticleClik here to view.
FDA Approves Once-Daily Coformulation of AbbVie's Viekira Regimen
The U.S. Food and Drug Administration (FDA) has approved a new once-daily coformulation of AbbVie's paritaprevir-based "3D" regimen for hepatitis C virus (HCV) genotype 1, to be sold as Viekira XR,...
View ArticleClik here to view.
Clik here to view.
INHSU 2016 Opens with Focus on Hepatitis C Prevention and Treatment for...
The 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) got underway Wednesday with an overview of the epidemiology of hepatitis C virus (HCV) among people who inject drugs...
View ArticleClik here to view.
INHSU 2016: Effective Antiviral Treatment Reduces Fatigue in People with...
Fatigue -- a common symptom among people living with hepatitis C virus (HCV) infection -- is associated with liver inflammation and fibrosis, but antiviral therapy that leads to a cure significantly...
View ArticleClik here to view.
INHSU 2016: Scaling Up Treatment in Prisons Could Help Halt Hepatitis C...
A substantial proportion of people with hepatitis C cycle through the criminal justice system, making prisons one of the most important settings for hepatitis C virus (HCV) prevention, testing, and...
View ArticleClik here to view.
INHSU 2016: Hepatitis C Vaccine Development Shows Progress but Scientific...
An effective vaccine may be necessary to eliminate hepatitis C virus (HCV), but development has been hampered by several challenges including the variability of the virus and incomplete natural...
View ArticleClik here to view.
INHSU 2016: HCV Treatment Effective and May Work as Prevention for People Who...
Hepatitis C treatment for people who inject drugs is as safe and effective as it is for non-drug-users -- with cure rates exceeding 90% -- and treating enough of this population could reduce...
View ArticleClik here to view.
INHSU 2016: Risk of Reinfection Is a Concern After Successful Hepatitis C...
People on opiate agonist substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier) -- achieving cure rates similar to those of the population as a whole -- but some people...
View ArticleClik here to view.
EASL Issues New Hepatitis C Treatment Recommendations For All Genotypes
The European Association for the Study of the Liver (EASL) released its latest recommendations on treatment of hepatitis C at a special meeting last week in Paris. The updated guidelines now include...
View ArticleClik here to view.
EASL Paris: 100% Cure Rate with AL-335, Odalasvir, and Simeprevir for 6 or 8...
A triple regimen containing 2 experimental hepatitis C drugs -- AL-335 and odalasvir -- plus simeprevir taken for either 6 or 8 weeks cured all previously untreated, non-cirrhotic patients with HCV...
View ArticleClik here to view.
EASL Paris: AbbVie 3D Regimen for 8 Weeks Cures Almost All HCV Genotype 1b...
AbbVie's paritaprevir-based 3D regimen taken for just 8 weeks without ribavirin led to sustained virological response in 98% of easier-to-treat non-cirrhotic patients with hepatitis C virus (HCV)...
View ArticleClik here to view.
Resources for People with HIV and Hepatitis in Disaster Areas
During and after disasters such as Hurricane Matthew, people with medical conditions including HIV and viral hepatitis will be among those displaced and requiring emergency care. Government agencies...
View ArticleClik here to view.
Response-Guided DAA Triple Regimen May Cure Hepatitis C in as Little as 3 Weeks
Response-guided therapy using 3 direct-acting antivirals without ribavirin cured a majority of easier-to-treat genotype 1b hepatitis C patients in just 3 weeks, according to results from a small pilot...
View ArticleClik here to view.
New Triple Combo Cures Most DAA-Experienced and Hard-to-Treat Hepatitis C...
An investigational 3-drug coformulation from Gilead Sciences produced sustained virological response (SVR) in 95% to 98% of hard-to-treat hepatitis C patients in the Phase 3 POLARIS trials, including...
View Article